If you have been reading about adsorption and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control after reconstitution usually includes visual inspection and instrumental analysis. A clear, particle-free solution is generally expected, but color and clarity can vary with sequence and buffer. Chromatographic separation can detect degradation products, while mass confirmation verifies molecular identity. pH measurement and osmolality checks may be relevant for certain applications. Documentation of lot number, solvent, and storage history supports reproducibility and helps distinguish preparation artifacts from sample degradation. Temperature logs and freeze-thaw counts add further context when results are reviewed.
After a peptide solution is prepared, its handling conditions influence how long it remains suitable for use. Solutions are typically separated into small portions to avoid repeated freeze-thaw cycles, which can promote aggregation or precipitation. Containers are chosen to minimize adsorption, especially for peptides that are hydrophobic or present at low concentration. Some laboratories use low-binding plastic tubes or add a carrier protein, although carrier addition can interfere with later analysis. Records usually note the solvent, date, and storage temperature for traceability.
Buffer components and ionic strength affect how a peptide dissolves and remains in solution. Some sequences require a defined pH range to avoid precipitation or aggregation, while others tolerate pure water. The optimal conditions are often determined empirically because solubility cannot be predicted reliably from sequence alone. Even when a peptide dissolves, the resulting solution may contain aggregates that are not visible to the eye. Analytical methods such as reversed-phase high-performance liquid chromatography and mass spectrometry are used to confirm identity and purity after reconstitution.
Peptide reconstitution is the process of dissolving a dried peptide preparation in a liquid solvent to form a solution. Many peptides are supplied as lyophilized powders because removing water improves stability during shipping and storage. The dried material may appear as a cake, flake, or loose powder depending on the manufacturing and drying method. Reconstitution restores the peptide to a liquid state so that it can be further diluted, analyzed, or handled in laboratory workflows. The term is distinct from dilution, which lowers concentration after a solution already exists.
| Property | Value | Notes |
|---|---|---|
| Appearance | Clear to slightly opalescent | Opalescence may indicate aggregation or undissolved material |
| Typical pH range | 3–7 for many peptides | Depends on sequence and buffer; measured after dissolution |
| Storage temperature (short term) | 2–8 °C | Refrigerated; limit repeated warming |
| Storage temperature (long term) | -20 °C or -80 °C | Freezing recommended for many research peptides |
| Common analytical method | RP-HPLC with UV detection | Purity and degradation profile can be monitored |
Concentration calculations depend on the amount of peptide present in the vial and the volume of solvent added. Lyophilized preparations often contain counterions, salts, or residual water, so the labeled mass may not equal the mass of the peptide itself. This difference can produce a calculated concentration that is higher than the true peptide concentration. Analytical determination of peptide content, rather than reliance on the vial label alone, reduces this source of error. Uncertainty in volume measurement also contributes, especially when small liquid volumes are handled.
Quality records typically include a certificate of analysis, batch number, molecular weight, purity result, and recommended storage conditions. After reconstitution, a laboratory log may record solvent, final volume, date, and storage location. Such documentation supports reproducibility and allows later investigation if a preparation behaves unexpectedly. Stability studies often examine purity and concentration over time under defined temperatures, but results are not universally transferable between peptides or formulations. Open questions remain about how best to predict aggregation for specific sequences and how much analytical testing is sufficient for routine laboratory work.
After a peptide is reconstituted, analytical checks can confirm identity, concentration, and purity. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry provides a mass value that supports sequence identity, while ultraviolet absorbance at 214 or 280 nanometers is often used for concentration estimation when the extinction coefficient is known. These methods answer different questions and are complementary. A single measurement rarely establishes full quality, because the same sample can appear acceptable by one method and fail another.
Once reconstituted, a peptide solution is generally less stable than the dry powder. Hydrolysis, oxidation, aggregation, and microbial growth can change the preparation over time, so storage temperature and duration are practical concerns. Dividing a solution into single-use aliquots before freezing can reduce repeated freeze-thaw cycles, which may otherwise cause precipitation or loss of activity. The optimal storage conditions vary by peptide, and no single rule applies to all sequences. Records of solvent, concentration, date, and storage history help maintain traceability. Studies often report stability under defined conditions rather than universal shelf lives.
Reconstitution is the process of dissolving a lyophilized peptide powder in a suitable liquid to produce a solution for laboratory or clinical use. The dry powder is typically a porous cake or fluffy solid formed by freeze-drying an aqueous or mixed-solvent preparation. Adding solvent restores the peptide to a dissolved state, but the result is not necessarily identical to the original pre-lyophilization solution. Factors such as pH, ionic strength, temperature, and the peptide's sequence influence how completely and quickly dissolution occurs. The term is distinct from dilution, which lowers concentration without changing the physical state of an already dissolved material.
Reconstitution involves considerably more than simply adding liquid. The solid must wet completely, and gentle mixing should avoid foaming, which can denature some peptides. Insoluble particles may indicate incomplete dissolution, aggregation, or insoluble excipients. The resulting concentration is calculated from the weighed peptide mass and the final volume, not from the volume of liquid added alone. Because peptides can adsorb to surfaces, container material and transfer steps can influence recovery, especially at low concentrations.
Peptide reconstitution refers to dissolving a dried peptide preparation in a liquid to form a solution. The dried form is often produced by lyophilization, a process that removes water under vacuum from a frozen sample. This yields a porous cake or powder that is more stable for transport and storage than many liquid formulations. The term reconstitution is also often used for other dried biological materials, so context matters greatly.
Analytical checks help determine whether a reconstituted peptide matches its expected identity and purity; reverse-phase high-performance liquid chromatography separates components by hydrophobicity and can reveal degradation products or impurities. Mass spectrometry provides a mass measurement that supports sequence identity when compared with the theoretical value. Ultraviolet absorbance at 280 nm can estimate concentration for peptides containing tryptophan or tyrosine, though sequence-dependent extinction coefficients are needed. For shorter or non-aromatic peptides, other methods such as amino acid analysis may be required. These techniques describe the material rather than guarantee its biological effect.
Cloudiness, particles, or gel formation after reconstitution can signal incomplete dissolution, aggregation, or contamination. A clear solution is not proof of purity, and a cloudy one is not always unusable if the peptide is designed to form suspensions. pH measurement can identify whether the solution matches the intended range, and buffer exchange may be needed when the original solvent is incompatible. Sterile filtration is sometimes used for microbial control, but filters can adsorb peptides and reduce concentration. Documentation of lot number, solvent, volume, date, and storage condition supports later traceability in laboratory records.
Once a peptide is in liquid form, its stability depends on temperature, pH, concentration, and the presence of oxygen or microbes. Refrigeration slows many degradation pathways, while freezing can extend storage for longer periods. Repeated freeze-thaw cycles are generally avoided because ice crystal formation and concentration changes can promote aggregation. Light exposure can also damage peptides that contain aromatic or sulfur-containing residues. A common laboratory practice is to divide a reconstituted stock into single-use aliquots before freezing, but the optimal storage condition remains peptide-specific and is often determined empirically.
== History == The association of elevated intraocular pressure (IOP) and glaucoma was first described by Englishman Richard Banister in 1622: "...that the Eye be grown more solid and hard, then naturally it should be...". Angle-closure glaucoma was treated with cataract extraction by John Collins Warren in Boston as early as 1806. The invention of the ophthalmoscope by Hermann Helmholtz in 1851 enabled ophthalmologists for the first time to identify the pathological hallmark of glaucoma, the excavation of the optic nerve head due to retinal ganglion cell loss. The first reliable instrument to measure intraocular pressure was invented by Norwegian ophthalmologist Hjalmar August Schiøtz in 1905. About half a century later, Hans Goldmann in Bern, Switzerland, developed his applanation tonometer, which, still today, despite numerous innovations in diagnostics, is considered the gold standard of determining this crucial pathogenic factor. In the late 20th century, further pathomechanisms beyond elevated IOP were discovered and became the subject of research, like insufficient blood supply, often associated with low or irregular blood pressure, to the retina and optic nerve head. The first drug to reduce IOP, pilocarpine, was introduced in the 1870s; other major innovations in pharmacological glaucoma therapy were the introduction of beta blocker eye drops in the 1970s and of prostaglandin analogues and topical (locally administered) carbonic anhydrase inhibitors in the mid-1990s.
=== Separation === The fact that berkelium readily assumes oxidation state +4 in solids, and is relatively stable in this state in liquids, greatly assists separation of berkelium from many other actinides. These are produced in relatively large amounts during the nuclear synthesis and often favor the +3 state. This fact was not yet known in the initial experiments, which used a more complex separation procedure. Various inorganic oxidation agents can be applied to the berkelium(III) solution to convert it to the +4 state, such as bromates (BrO−3), bismuthates (BiO−3), chromates (CrO2−4 and Cr2O2−7), silver(I) thiolate (Ag2S2O8), lead(IV) oxide (PbO2), ozone (O3), or photochemical oxidation procedures. More recently, it has been discovered that some organic and bio-inspired molecules, such as the chelator 3,4,3-LI(1,2-HOPO), can also oxidize Bk(III) and stabilize Bk(IV) under mild conditions. Berkelium(IV) is then extracted with ion exchange, extraction chromatography or liquid-liquid extraction using HDEHP (bis-(2-ethylhexyl) phosphoric acid), amines, tributyl phosphate or various other reagents. These procedures separate berkelium from most trivalent actinides and lanthanides, except for the lanthanide cerium (lanthanides are absent in the irradiation target but are created in various nuclear fission decay chains). A more detailed procedure adopted at the Oak Ridge National Laboratory was as follows: the initial mixture of actinides is processed with ion exchange using lithium chloride reagent, then precipitated as hydroxides, filtered and dissolved in nitric acid.
== Composition == Tecemotide is a synthetic lipopeptide that is 27 amino acids long. Its molecular formula is C124H203N33O38, and its amino acid sequence is S T A PPAH G VTSAPDTRPAPGSTAPPKG. The first 25 amino acids of tecemotide are derived from the mucin 1 (MUC1, carcinoma-associated mucin, episialin, or CD227) sequence. The 26th modified amino acid, K, is palmityl-lysine (N6-(1-oxohexadecyl)-L-lysine), and the 27th is glycine.
== Protein Intake and Muscle Hypertrophy == Research on resistance training shows that increasing daily protein intake supports gains in muscle mass, but the benefit have diminishing returns. A large meta-analysis by Morton et al. (2018) found that muscle growth increases as protein intake rises up to about 1.6 g/kg/day, after which additional protein offers little added effect. A similar dose response analysis by Tagawa et al. (2020) reported that while higher protein intakes are generally associated with greater lean mass gains, the effect plateaus once basic requirements for resistance trained individuals are met. Together, these findings suggest that moderate but adequate protein intake is sufficient for maximizing hypertrophy in most healthy adults.
== Products == The company's research and development activities are focused on drugs for the treatment of severe, resistant bacterial infections and life-threatening, invasive fungal diseases. Basilea's products are aimed at diseases that have so far been insufficiently treatable. The company markets the following products exclusively through licence and distribution partners: Ceftobiprole (trade name Zevtera/Mabelio) is a broad-spectrum antibiotic administered intravenously for community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) in adults. It has an active effect against the bacterium Staphylococcus aureus (MRSA), including methicillin-resistant strains, and against penicillin-resistant Streptococcus pneumoniae (PRSP) bacteria, as well as against gram-negative pathogens such as Enterobacteriaceae. Isavuconazole (trade name Cresemba) is an intravenous and oral antifungal agent for the treatment of patients with invasive aspergillosis and invasive mucormycosis. While Astellas is responsible for the commercialisation of Cresemba in the USA, the pharmaceutical group Pfizer covers the commercialisation in most of Europe and also distributes Cresemba in China and the Asia–Pacific (APAC) area. Basilea's distribution partner in the MENA region is Hikma Pharmaceuticals LLC; Knight Therapeutics Inc. commercialises the antifungal Cresemba in South America.
Sources: en.wikipedia.org
SpyTag and SpyCatcher were formed from the splitting and engineering of the CnaB2 domain of the FbaB protein from Streptococcus pyogenes, which naturally forms an intramolecular isopeptide bond to assist colonization of the host cell. With the formation of the isopeptide bond, the CnaB2 domain becomes more tolerant to conformational, thermal and pH changes. Building upon this, SpyTag was obtained from CnaB2 by extracting the C-terminal beta strand containing the reactive aspartic acid at D556 and leaving the rest of the beta strands containing the reactive lysine K470 and the catalytic glutamic acid at E516 to become SpyCatcher, after further engineering to remove some hydrophobic surface residues. The resulting SpyTag/SpyCatcher can react to form the isopeptide bond with a second-order rate constant of 1.4 ± 0.4 × 103 M−1 s−1. It is postulated that the reaction mechanism proceeds by a nucleophilic attack on D556 from K470, mediated by E516. By reconstituting SpyTag:SpyCatcher, the resulting conjugated complex acquires the stability of the parent CnaB2 domain. A second generation SpyTag/SpyCatcher called SpyTag002/SpyCatcher002 was then created through phage display that enables the peptide-protein pair to react up to 12 times faster than the original pair, at a rate constant of 2.0 ± 0.2 × 104 M−1 s−1. The second generation SpyCatcher002 also has abolished self-reactivity that is present with SpyCatcher. A third generation SpyTag/SpyCatcher called SpyTag003/SpyCatcher003 has now also been created through rational design.
Combining an adsorbent with a refrigerant, adsorption chillers use heat to provide a cooling effect. This heat, in the form of hot water, may come from any number of industrial sources including waste heat from industrial processes, prime heat from solar thermal installations or from the exhaust or water jacket heat of a piston engine or turbine. Although there are similarities between adsorption chillers and absorption refrigeration, the former is based on the interaction between gases and solids. The adsorption chamber of the chiller is filled with a solid material (for example zeolite, silica gel, alumina, active carbon or certain types of metal salts), which in its neutral state has adsorbed the refrigerant. When heated, the solid desorbs (releases) refrigerant vapour, which subsequently is cooled and liquefied. This liquid refrigerant then provides a cooling effect at the evaporator from its enthalpy of vaporization. In the final stage the refrigerant vapour is (re)adsorbed into the solid. As an adsorption chiller requires no compressor, it is relatively quiet.
== Phosphinic peptides == Phosphinic peptides are pseudo-peptides where a phosphinic acid bond (PO2-CH-) has replaced a peptide bond in the peptide analogue sequence. To some extent the chemical structure of phosphinic peptides is similar to that of intermediates which are produced in hydrolysis of peptides by proteolytic enzymes. The hypothesis has been made that these pseudo-peptides mimic the structure of the enzyme substrates in their transition state and crystallography of zinc proteases in complex with phosphinic peptides supports that hypothesis.
== Olfactory perception == The properties of a compound relating to human olfactory perception includes its odour quality, threshold and intensity as a function of its concentration. The odour quality of a (odour-active) compound is assessed using odour descriptors in sensory descriptive analyses. It shows the sensory–chemical relationship in volatile compounds. The odour quality of a compound may change with its concentration. The absolute threshold of a compound is the minimum concentration at which it can be detected. In a mixture of volatile compounds, only the proportion of compounds present at concentrations above their threshold contribute to the odour. This property can be represented by the odour threshold (OT), the minimum concentration at which the odour is perceived by 50% of a human panel without determining its quality, or the recognition threshold, the minimum concentration at which the odour is perceived and can be described by 50% of a human panel. The intensity of perception of a compound is positively correlated with its concentration. It is represented by the unique psychometric or concentration-response function of the compound.
Sources: en.wikipedia.org
=== Atomic number === In chemistry, the number of protons in the nucleus of an atom is known as the atomic number, which determines the chemical element to which the atom belongs. For example, the atomic number of chlorine is 17; this means that each chlorine atom has 17 protons and that all atoms with 17 protons are chlorine atoms. The chemical properties of each atom are determined by the number of (negatively charged) electrons, which for neutral atoms is equal to the number of (positive) protons so that the total charge is zero. For example, a neutral chlorine atom has 17 protons and 17 electrons, whereas a Cl− anion has 17 protons and 18 electrons for a total charge of −1 e. All atoms of a given element are not necessarily identical, however. The number of neutrons may vary to form different isotopes, and energy levels may differ, resulting in different nuclear isomers. For example, there are two stable isotopes of chlorine: 3517Cl with 35 − 17 = 18 neutrons and 3717Cl with 37 − 17 = 20 neutrons.
Along with Singapore, South Korea, and Taiwan, Hong Kong is one of the Four Asian Tigers. One of the world's most significant financial centres and commercial ports, Hong Kong has a market economy focused on services, characterised by low taxation, minimal government market intervention, and an established international financial market. It is the world's 39th-largest economy, with a nominal GDP of approximately US$446 billion. Hong Kong is highly developed, and ranks fourth on the UN Human Development Index. The Hong Kong Stock Exchange is the fifth-largest in the world, with a market capitalisation of HK$48.2 trillion (US$6.17 trillion) as of December 2025. Hong Kong was ranked as the 15th most innovative territory in the 2025 Global Innovation Index, and 3rd in the Global Financial Centres Index. The city is sometimes referred to as "Silicon Harbour" in the 1990s, a nickname derived from Silicon Valley in California. Hong Kong is the ninth largest trading entity in exports and eighth largest in imports (2021), trading more goods in value than its gross domestic product. Over half of its cargo throughput consists of transshipments (goods travelling through Hong Kong). Products from mainland China account for about 40% of that traffic. The city's location allowed it to establish a transportation and logistics infrastructure, which includes the world's seventh-busiest container port and the busiest airport for international cargo. The territory's largest export markets are mainland China and the United States. Hong Kong is a key part of the 21st Century Maritime Silk Road.
==== Hydroxyurea ==== Hydroxyurea is another drug that can sometimes be administered to relieve anemia caused by beta-thalassemia. This is achieved, in part, by reactivating fetal haemoglobin production; however its effectiveness is uncertain.
The order Hareavirales includes the families Arenaviridae, Nairoviridae and Phenuiviridae The family Arenaviridae includes the viruses responsible for Lassa fever (Lassa virus), Lujo virus, Argentine (Junin virus), Bolivian (Machupo virus), Brazilian (Sabiá virus), Chapare hemorrhagic fever (Chapare virus), Venezuelan (Guanarito virus), and Whitewater Arroyo virus hemorrhagic fevers. The family Nairoviridae includes the Crimean-Congo hemorrhagic fever (CCHF) virus from the genus Orthonairovirus. The family Phenuiviridae includes the Rift Valley fever (RVF) virus from the genus Phlebovirus. The order Elliovirales includes the families Peribunyaviridae and Hantaviridae. The family Hantaviridae includes the causative agents of Hantavirus hemorrhagic fever with renal syndrome (HV-HFRS). The family Peribunyaviridae includes the Ngari virus. The order Mononegavirales contains the family Filoviridae. The family Filoviridae includes Ebola virus and Marburg virus. The order Amarillovirales includes the family Flaviviridae. The family Flaviviridae includes dengue, yellow fever, and two viruses in the tick-borne encephalitis group that cause VHF: Omsk hemorrhagic fever virus and Kyasanur Forest disease virus. In September 2012 scientists reported the discovery of a member of the Rhabdoviridae family potentially causing hemorrhagic fever. In a 2009 outbreak of acute hemorrhagic fever they discovered a new viral genome in one of the three people affected. The virus was named Bas-Congo virus.
== External links == Legio X – Legio X Gemina (Equites) – "Viri Clarissimi" Livius.org: List of Roman legions Archived 2014-06-26 at the Wayback Machine A catalogue of Roman legions Legio V Living History Group in Tennessee Roman legions from Dacia (KML file) Archived 2012-01-20 at the Wayback Machine
Sources: en.wikipedia.org
Refrigeration is common for short-term use, while freezing at -20 °C or -80 °C is common for longer periods. Aliquots reduce repeated temperature changes. Exact conditions depend on the peptide and buffer.
Repeated freeze-thaw cycles can cause aggregation, precipitation, or adsorption losses. Dividing a solution into single-use portions limits those changes. The practice also makes handling more consistent.
Undissolved powder, aggregated peptide, or precipitated buffer salts can produce visible particles. Some particles appear only after freezing or pH changes. Filtration and analytical checks can help identify the source.
It is the addition of a liquid to a dried peptide to produce a solution. The procedure changes the physical form, not the chemical identity of the peptide. It is a routine step in laboratory handling.